Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AR-100: Phase I data

In a 10-day Phase I study in healthy volunteers,

Read the full 98 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE